Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Journal of Neurochemistry

Volumn 85, Issue 6, 2003, Pages 1359-1367

  Dedeoglu, Alpaslan ^a,b   Kubilus, James K ^a,b   Yang, Lichuan ^c   Ferrante, Kimberly L ^d   Hersch, Steven M ^d   Beal, M Flint ^c   Ferrante, Robert J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Creatine; Huntington's disease

Indexed keywords

CREATINE; HUNTINGTIN; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; WEIGHT REDUCTION;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; BRAIN; CORPUS STRIATUM; CREATINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEOSTRIATUM; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALIA; MUS MUSCULUS;

EID: 0038115294     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01706.x     Document Type: Article

References (44)

1. Andreassen O. A., Dedeoglu A., Ferrante R. J., Jenkins B. G., Ferrante K. L., Thomas M., Borchelt D. R., Hersch S. M., Ross C. R. and Beal M. F. (2001a) Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. J. Neurobiol. 8, 479-491.
2. Andreassen O. A., Ferrante R. J., Huang H. M., Dedeoglu A., Park L., Ferrante K. L., Kwon J., Borchelt D. R., Ross C. A., Gibson G. E. and Beal M. F. (2001b) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neurol. 50, 112-117.
3. Andreassen O. A., Ferrante R. J., Dedeoglu A. and Beal M. F. (2001c) Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 29, 3371-3373.
4. Balestrino M., Lensman M., Parodi M., Perasso L., Rebaudo R., Melani R., Polenov S. and Cupello A. (2002) Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage. Amino Acids 23, 221-229.
5. Beal M. F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. TINS 23, 298-304.
6. Beal M. F., Brouillet E., Jenkins B., Henshaw R., Rosen B. and Hyman B. T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61, 1147-1150.
7. Benzi G. (2000) Is there a rationale for the use of creatine either as nutritional supplementation or drug administration in humans participating in sport? Pharmacol. Res. 41, 255-264.
8. Bogdanov M. B., Andreassen O. A., Dedeoglu A., Ferrante R. J. and Beal M. F. (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79, 1246-1249.
9. Brouillet E., Hantraye P., Ferrante R. J., Dolan R., Leroy-Willig A., Kowall N. W. and Beal M. F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA 92, 7105-7109.
10. Browne S. E., Ferrante R. J. and Beal M. F. (1999) Oxidative stress in Huntington's disease. Brain Pathol. 9, 147-163.
11. Carter A. J., Muller R. E., Pschom U. and Stransky W. (1995) Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J. Neurochem. 6, 2691-2699.
12. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiari L. and Bates G. P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
13. Dedeoglu A., Kubilus J. K., Jeitner T. M., Matson S. A., Bogdanov M., Kowall N. W., Matson W. R., Cooper A. J., Ratan R. R., Beal M. F., Hersch S. M. and Ferrante R. J. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 20, 8942-8950.
14. 2+ exchanger. Exp. Neurol. 145, 38-45.
15. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P. and Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
16. Ferrante R. J., Andreassen O. A., Jenkins B. G., Dedeoglu A., Kuemmerle S., Kubilus J. K., Kaddurah-Daouk R., Hersch S. M. and Beal M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397.
17. Ferrante R. J., Andreassen O. A., Dedeoglu A., Ferrante K. L., Jenkins B. G., Hersch S. M. and Beal M. F. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22, 1592-1599.
18. Franklin K. B. J. and Paxinos G. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
19. Gu M., Gash M. T, Mann V. M., Javoy-Agid F., Cooper J. M. and Schapira A. H. V. (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385-389.
20. Hemmer W. and Wallimann T. (1993) Functional aspects of creatine kinase in brain. Dev. Neurosci. 15, 249-260.
21. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
22. Jenkins B. G., Klivenyi P., Kustermann E., Andreassen O. A., Ferrante R. J., Rosen B. R. and Beal M. F. (2000) Non-linear decrease over time in N-acetylaspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 74, 2108-2119.
23. Kieburtz K. (2001) Placebo-controlled trial of creatine in Huntington's disease. Neurol. Abstract. 56, A386.
24. Klivenyi P., Ferrante R. J., Matthews R. T., Bogdanov M. B., Klein A. M., Andreassen O. A., Mueller G., Wermer M., Kaddurah-Daouk R. and Beal M. F. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347-350.
25. Koroshetz W. J., Jenkins B. G., Rosen B. R. and Beal M. F. (1997) Energy metabolism defects in Huntington's disease and possible therapy with coenzyme Q10. Ann. Neurol. 41, 160-165.
26. Kuemmerle S., Gutekunst C. A., Klein A. M., Li X. J., Li S. H., Beal M. F., Hersch S. M. and Ferrante R. J. (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849.
27. Lawler J. M., Bames W. S., Wu G., Song W. and Demaree S. (2002) Direct antioxidant properties of creatine. Biochem. Biophys. Res. Commun. 1, 47-52.
28. Ludolph A. C., He F., Spencer P. S., Hammerstad J. and Sabri M. (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 4, 492-498.
29. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W. and Bates G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
30. Matthews R. T., Yang L., Jenkins B. G., Ferrante R. J., Rosen B. R., Kaddurah-Daouk R. and Beal M. F. (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18, 156-163.
31. Matthews R. T., Ferrante R. J., Klivenyi P., Yang L., Klein A. M., Mueller G., Kaddurah-Daouk R. and Beal M. F. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157, 142-149.
32. O'Gorman E., Beutner G., Wallimann T and Brdiczka D. (1996) Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim. Biophys. Acta 1276, 161-170.
33. Ohtsuki S., Tachikawa M., Takanaga H., Shimizu H., Watanabe M., Hosoya K. and Terasaki T. (2002) The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J. Cereb. Blood Flow Metab. 22, 1327-1335.
34. Panov A. V., Gutekunst C. A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J. and Greenamyre J. T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 8, 731-736.
35. Sawa A., Wiegand G. W., Cooper J., Margolis R. L., Sharp A. H., Lawler J. F. Jr, Greenamyre J. T, Snyder S. H. and Ross C. A. (1999) Increased apoptosis of Huntington's disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5, 1194-1198.
36. Schulz J. B., Matthews R. T., Jenkins B. G., Ferrante R. J., Siwek D., Henshaw D. R., Cipolloni P. B., Mecocci P., Kowall N. W., Rosen B. R. and Beal M. F. (1995a) Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 12, 8419-8429.
37. Schulz J. B., Henshaw D. R., Siwek D., Jenkins B. G., Ferrante R. J., Cipolloni P. B., Kowall N. W., Rosen B. R. and Beal M. F. (1995b) Involvement of free radicals in excitotoxicity in vivo. J. Neurochem. 5, 2239-2247.
38. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell 89, 93-103.
39. Tamopolsky M. A. and Beal M. F. (2001) Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 5, 561-574.
40. Verbessem P. (2002) Oral creatine supplementation in patients with Huntington's disease. Neurol. Abstract. 58, A334.
41. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. and Richardson E. P. Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
42. Wallimann T., Wyss M., Brdiczka D., Nicolay K. and Eppenberger H. M. (1992) Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem. J. 281, 21-40.
43. Wyss M. and Schulze A. (2002) Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience 2, 243-260.
44. Xu C. J., Klunk W. E., Kanfer J. N., Xiong Q., Miller G. and Pettegrew J. W. (1996) Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J. Biol. Chem. 271, 13435-13440.